Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Average Rating of “Moderate Buy” from Analysts

Viridian Therapeutics, Inc. (NASDAQ:VRDN) has been given a consensus recommendation of “Moderate Buy” by the twelve analysts that are covering the company, MarketBeat.com reports. Three analysts have rated the stock with a hold recommendation and nine have given a buy recommendation to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $35.70.

VRDN has been the topic of several analyst reports. Needham & Company LLC reaffirmed a “buy” rating and set a $38.00 price target on shares of Viridian Therapeutics in a research note on Tuesday, January 7th. Royal Bank of Canada upped their target price on Viridian Therapeutics from $44.00 to $47.00 and gave the company an “outperform” rating in a research report on Tuesday, December 17th. TD Cowen assumed coverage on shares of Viridian Therapeutics in a research report on Monday, November 25th. They set a “buy” rating for the company. Wells Fargo & Company restated an “equal weight” rating and issued a $27.00 price target (down previously from $37.00) on shares of Viridian Therapeutics in a research note on Thursday, December 19th. Finally, HC Wainwright reiterated a “buy” rating and set a $34.00 price objective on shares of Viridian Therapeutics in a research note on Monday, December 16th.

Viridian Therapeutics Price Performance

VRDN stock opened at $19.85 on Wednesday. The company has a market cap of $1.57 billion, a PE ratio of -4.61 and a beta of 1.13. The company has a current ratio of 18.55, a quick ratio of 18.55 and a debt-to-equity ratio of 0.04. The stock has a 50-day moving average price of $19.34 and a two-hundred day moving average price of $19.56. Viridian Therapeutics has a 12-month low of $11.40 and a 12-month high of $27.20.

Viridian Therapeutics (NASDAQ:VRDN) last issued its earnings results on Tuesday, November 12th. The company reported ($1.15) EPS for the quarter, missing analysts’ consensus estimates of ($1.11) by ($0.04). Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%. The business had revenue of $0.09 million during the quarter, compared to analysts’ expectations of $0.08 million. As a group, research analysts predict that Viridian Therapeutics will post -4.03 EPS for the current year.

Hedge Funds Weigh In On Viridian Therapeutics

Large investors have recently bought and sold shares of the business. R Squared Ltd bought a new position in shares of Viridian Therapeutics during the fourth quarter valued at approximately $26,000. Point72 Asia Singapore Pte. Ltd. bought a new position in Viridian Therapeutics during the 3rd quarter worth $149,000. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in Viridian Therapeutics in the third quarter worth $208,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Viridian Therapeutics by 17.0% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,997 shares of the company’s stock valued at $318,000 after buying an additional 2,036 shares during the last quarter. Finally, AlphaCentric Advisors LLC boosted its holdings in shares of Viridian Therapeutics by 20.0% during the third quarter. AlphaCentric Advisors LLC now owns 15,000 shares of the company’s stock valued at $341,000 after acquiring an additional 2,500 shares during the period.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.